OPT Company Profile and Key Details
NASDAQ : OPT
Opthea
$3.41
0.05+1.49%
At Close 4:00 PMNot Actively Trading
50
BESG ScoreESG Rating
Price Chart
Stock Price Today
Opthea Limited (OPT) stock surged +1.49%, trading at $3.41 on NASDAQ, up from the previous close of $3.36. The stock opened at $3.41, fluctuating between $3.41 and $3.41 in the recent session.
Stock Snapshot
3.36
Prev. Close
4.24B
Market Cap
3.41
Day Low
-1.5155555555555555
P/E Ratio
-2.25
EPS (TTM)
-1.63
Cash Flow per Share
3.41
Open
1.24B
Number of Shares
3.41
Day High
510.69%
Free Float in %
-0.63
Book Value
3.03K
Volume
Relevant Articles
SEC Fillings
Current Report (8-k)
| Filing Date | Accepted Date | |
|---|---|---|
Annual Report (10-k)
| Filing Date | Accepted Date | |
|---|---|---|
Stock Price History Chart
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Apr 01, 2025 | 3.41 | 3.41 | 3.41 | 3.41 | 0 |
| Mar 27, 2025 | 3.41 | 3.41 | 3.41 | 3.41 | 0 |
| Mar 26, 2025 | 3.41 | 3.41 | 3.41 | 3.41 | 0 |
| Mar 25, 2025 | 3.41 | 3.41 | 3.41 | 3.41 | 0 |
| Mar 24, 2025 | 3.41 | 3.41 | 3.41 | 3.41 | 0 |
| Mar 21, 2025 | 3.41 | 3.41 | 3.41 | 3.41 | 0 |
| Mar 19, 2025 | 3.41 | 3.41 | 3.41 | 3.41 | 0 |
| Mar 17, 2025 | 3.48 | 3.48 | 3.25 | 3.41 | 3.03K |
| Mar 14, 2025 | 3.22 | 3.45 | 3.03 | 3.18 | 86.41K |
| Mar 13, 2025 | 3.15 | 3.26 | 3.03 | 3.07 | 15.46K |
| Mar 12, 2025 | 3.14 | 3.32 | 3.13 | 3.17 | 18.4K |
| Mar 11, 2025 | 3.20 | 3.52 | 3.06 | 3.13 | 43.6K |
| Mar 10, 2025 | 3.41 | 3.41 | 3.20 | 3.24 | 44.11K |
| Mar 07, 2025 | 3.52 | 3.96 | 3.43 | 3.51 | 53.43K |
| Mar 06, 2025 | 3.83 | 4.08 | 3.52 | 3.52 | 37.73K |
| Mar 05, 2025 | 4.18 | 4.18 | 3.74 | 3.98 | 54.46K |
| Mar 04, 2025 | 5.11 | 5.17 | 3.35 | 3.55 | 139.73K |
| Mar 03, 2025 | 4.46 | 5.54 | 4.46 | 5.11 | 120.83K |
| Feb 28, 2025 | 4.71 | 4.71 | 4.28 | 4.48 | 47.34K |
| Feb 27, 2025 | 4.71 | 5.17 | 4.53 | 4.60 | 20.92K |
Contact Details
About Company
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
Company Information
| Employees | 33 |
| Beta | 1.67 |
| Sales or Revenue | $25.00K |
| 5Y Sales Change% | -0.964% |
| Fiscal Year Ends | June |
| Sector | Healthcare |
| Industry | Biotechnology |
Stock Peers
REGN
-14.93-1.97%
Regeneron Pharmaceuticals, Inc.$744.12ARGX-21.26-3.01%
argenx SE$684.77UTHR-9.67-1.79%
United Therapeutics Corporation$530.35VRTX-10.9-2.36%
Vertex Pharmaceuticals Incorporated$451.59MDGL-1.18-0.27%
Madrigal Pharmaceuticals, Inc.$442.00KRTX0.09+0.03%
Karuna Therapeutics, Inc.$329.83ALNY-5.62-1.75%
Alnylam Pharmaceuticals, Inc.$314.80PRAX-14.59-4.81%
Praxis Precision Medicines, Inc.$288.79KRYS-5.5-2.15%
Krystal Biotech, Inc.$250.83SGEN-0.16-0.07%
Seagen Inc.$228.74Company Overview
Opthea Limited (NASDAQ:OPT) closed at $3.41 USD, gaining $0.05 (1.49%) from the previous close of $3.36. The stock is currently mid-range between its 52-week high and low $1.79 and $6.30. With a market capitalization of about $4.24 billion, Opthea Limited is classified as a mid-cap and shows higher-than-market volatility (beta ~1.67). Key stats such as the average daily volume over the past year has been around 32.32 thousand shares, volume is running light vs its 52-week average. Headquartered in South Yarra, VIC, Opthea Limited operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir,, the company employs approximately 33 people and listed since October 16, 2020. Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia.
Technical Performance
Short-term trend indicators are mixed aligned (SMA20 -16.9%, SMA50 -22.97%, SMA200 -2.83%). The stock’s 14-day RSI is 39.28 (weak momentum), while the ATR of 0.45 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -45.87% below its high and over 90.5% above its low.
Dividend & Fair Value
Opthea Limited last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.22. This means the shares are trading above this model’s fair value.
Earnings & Analyst Outlook
Opthea Limited generated EPS of -$2.32 over the past year. Five-year average earnings growth is -44.08%. Wall Street analysts project EPS growth of 68.97% annually over the next five years. The latest quarter delivered EPS of -$0.20. The next quarter is forecast at -$0.29. Next year's EPS is expected at $21.44. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 0 Buy ratings, 2 Hold ratings, 0 Sell rating and 1 Strong Sell ratings. Price targets range from $2.00 to $1.00. The high target offers -41.35% upside. The low target suggests -70.67% downside. The mean target is $1.33. This offers -61.0% upside. Opthea Limited earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 28, 2025, missed forecasts by 345.47%. The prior quarter beat by 137.1%. Over the last six quarters, Apple has recorded several small beats. These include 123.64% in August 21, 2024.
Shareholding & Insider Activity
Opthea Limited has 153.91 million shares outstanding. The public float is 785.98 million shares, elevated short interest at 0.47% of float. This equals 533.75 thousand shares. The short ratio is 3895.99 days. Institutional investors hold 4.52% of the float. Insiders own 0.0%.
Frequently Asked Questions
What is the current Opthea Limited (OPT) stock price?
Opthea Limited (NASDAQ: OPT) stock price is $3.41 in the last trading session. During the trading session, OPT stock reached the peak price of $3.41 while $3.41 was the lowest point it dropped to. The percentage change in OPT stock occurred in the recent session was 1.49% while the dollar amount for the price change in OPT stock was $0.05.
OPT's industry and sector of operation?
The NASDAQ listed OPT is part of Biotechnology industry that operates in the broader Healthcare sector. Opthea Limited designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Who are the executives of OPT?
Ms. Annie Lee
Fin. & Operations Mang.
Ms. Judith J. Robertson B.A., M.B.A.
Chief Commercial Officer
Mr. Timothy E. Morris CPA, CPA
Chief Financial Officer
Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D.
MD, Chief Executive Officer & Executive Director
Mr. Bruno Gagnon BPHARM, M.Sc.
Senior Vice President of Global Clinical Operations
Dr. Joel Naor M.D., MBA, MSc
Chief Medical Officer
Dr. James Goding
Independent Consultant
Mr. Timothy E. Morris C.P.A., CPA
Chief Financial Officer
Dr. Ian Leitch
Director of Clinical Research
Dr. Michael Gerometta Ph.D.
Head of Chemistry, Manufacturing & Controls Devel.
Ms. Karen Adams CPA
Vice President of Fin. & Company Sec.
Dr. Kenneth Sall
Chief Medical Officer
Ms. Karen Adams C.P.A.
Vice President of Fin. & Company Sec.
Mr. Timothy E. Morris CPA, Ph.D.
Chief Financial Officer
Fin. & Operations Mang.
Ms. Judith J. Robertson B.A., M.B.A.
Chief Commercial Officer
Mr. Timothy E. Morris CPA, CPA
Chief Financial Officer
Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D.
MD, Chief Executive Officer & Executive Director
Mr. Bruno Gagnon BPHARM, M.Sc.
Senior Vice President of Global Clinical Operations
Dr. Joel Naor M.D., MBA, MSc
Chief Medical Officer
Dr. James Goding
Independent Consultant
Mr. Timothy E. Morris C.P.A., CPA
Chief Financial Officer
Dr. Ian Leitch
Director of Clinical Research
Dr. Michael Gerometta Ph.D.
Head of Chemistry, Manufacturing & Controls Devel.
Ms. Karen Adams CPA
Vice President of Fin. & Company Sec.
Dr. Kenneth Sall
Chief Medical Officer
Ms. Karen Adams C.P.A.
Vice President of Fin. & Company Sec.
Mr. Timothy E. Morris CPA, Ph.D.
Chief Financial Officer
How OPT did perform over past 52-week?
OPT's closing price is 90.5% higher than its 52-week low of $1.79 where as its distance from 52-week high of $6.30 is -45.87%.
How many employees does OPT have?
Number of OPT employees currently stands at 33.
Link for OPT official website?
Official Website of OPT is: https://www.opthea.com
How do I contact OPT?
OPT could be contacted at phone 613 982 60399 and can also be accessed through its website. OPT operates from 650 Chapel Street, South Yarra, VIC 3141, Australia.
How many shares of OPT are traded daily?
OPT stock volume for the day was 3.03K shares. The average number of OPT shares traded daily for last 3 months was 32.32K.
What is the market cap of OPT currently?
The market value of OPT currently stands at $4.24B with its latest stock price at $3.41 and 1.24B of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.
© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep